Viking Therapeutics Posts Wider Q2 Loss

Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on treatments for obesity and metabolic diseases, released results for its second quarter on July 23, 2025. The key takeaway from the update was a higher-than-expected net loss (GAAP) for Q2 2025, driven by a sharp increase in research and development spending to support pipeline progress, particularly in later-stage obesity trials. The company reported a net loss per share of $(0.58) (GAAP), wider than the consensus GAAP estimate of $(0.45). There was no revenue reported or expected, in line with its clinical-stage status. Despite the larger operating loss and elevated cash burn, the company finished the quarter with significant liquidity, allowing it to continue funding large clinical programs. Overall, the period highlighted both progress and risks tied to advancing its lead drug candidate against strong competition. Source: Analyst estimates for the quarter provided by FactSet. Viking Therapeutics develops therapies for diseases tied to metabolism, with a pipeline that includes treatments for obesity, nonalcoholic steatohepatitis (a type of fatty liver disease often called NASH or MASH), and rare genetic disorders. Its business model centers on drug discovery and clinical development, aiming to secure approvals from regulators like the Food and Drug Administration (FDA) for products that meet areas of high unmet need.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool